SINOVAC BIOTECH LTD

Drug Name	Phase	Indication	Designations	Patent
36-71 months old children-experimental EV71 vaccine.	Phase 3	Hand, Foot and Mouth Disease	-	-
investigational 23-valent PPV	Phase 3	Pneumococcal Infections	-	-
400U /0.5ml EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-	-
Investigational sIPV	Phase 3	Poliomyelitis	-	-
three consecutive lots of EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-	-
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine	Phase 3	Seasonal Influenza	-	-
Sabin Strain Inactivated Poliovirus Vaccine	Phase 3	Poliomyelitis	-	-
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV	Phase 3	Influenza	-	-
Investigational tetanus vaccine, adsorbed	Phase 3	Tetanus	-	-
Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14	Phase 3	Covid19	-	-
Vaccine manufactured at commercialized scale	Phase 3	Varicella	-	-
Sinovac PCV13	Phase 3	Pneumococcal Infectious Disease	-	-
investigational live attenuated mumps vaccine	Phase 3	Mumps	-	-
control live attenuated mumps vaccine	Phase 3	Mumps	-	-
Inactivated COVID-19 Vaccine	Phase 3	COVID-19	-	-
Investigational live attenuated varicella vaccine	Phase 3	Varicella	-	-
COVID-19 Vaccine,Inactivated	Phase 3	COVID-19	-	-
Varicella Vaccine	Phase 3	Varicella	-	-
COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)	Phase 3	COVID-19	-	-
Sinovac rabies vaccine	Phase 3	Rabies (Healthy Volunteers)	-	-
sIPV-sIPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-	-
Trivalent influenza vaccine (contains B/Victoria strain)	Phase 3	Seasonal Influenza	-	-
sIPV-bOPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine(0.5ml)	Phase 3	Seasonal Influenza	-	-
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent	Phase 3	Seasonal Influenza	-	-
Experimental vaccine	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine(0.25ml)	Phase 3	Seasonal Influenza	-	-
bivalent enterovirus vaccine (Vero cell), inactivated	Phase 3	Hand, Foot, and Mouth Disease（HFMD)	-	-
Single-dose regimen of high dosage investigational sIPV	Phase 2	Poliomyelitis	-	-
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated	Phase 2	Hand, Foot and Mouth Disease	-	-
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)	Phase 2	Hand, Foot, and Mouth Disease (HFMD)	-	-
pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Pandemic Influenza	-	-
100U EV71 vaccine with adjuvant	Phase 2	Infection, Viral, Enterovirus	-	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-	-
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Influenza	-	-
Oral hexavalent reassortant rotavirus attenuated live vaccine	Phase 2	Rotavirus Gastroenteritis	-	-
COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain	Phase 2	COVID-19	-	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule	Phase 2	COVID-19	-	-
SARS-CoV-2 Inactivated Vaccine	Phase 2	COVID-19	-	-
Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-	-
Sinovac PCV24	Phase 2	Pneumococcal Infectious Disease	-	-
Low-dose experimental vaccine	Phase 2	Herpes Zoster	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

SINOVAC BIOTECH LTD

Market Overview

SVA News

Catalyst Timeline

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV Phase 3 Results Expected

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals